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We studied the interaction of African trypanosomes with human complement. Bloodstream forms of
Trypanosoma brucei subsp. gambiense isolated from mice activated the alternative pathway of complement
during a 30-min incubation in vitro. In human serum, all cells remained intact and motile during this period.
C3 was detected on the surface by a direct binding assay with a monoclonal antibody which recognizes C3b and
iC3b. C3 deposition could also be detected by this radioimmunoassay when parasites were incubated with
purified C3. Such C3 binding was enhanced by factor B, factor D, and magnesium. Surface deposition of factor
B was demonstrated both by flow immunofluorescence analysis and binding of radiolabeled factor B. C3
binding and factor B binding were inhibitable by EDTA but not by ethylene glycol-bis(O-aminoethyl
ether)-N,N,N',N'-tetraacetic acid (EGTA). The inhibited binding could be restored by addition of magnesium.
No human immunoglobulin G or mouse immunoglobulin was detected on the trypanosome surface. By flow
cytometry, neither human C5 nor polymerized C9 was detected on trypanosomes incubated in serum, although
this assay was able to detect C5 and C9 on the surface of complement-treated human erythrocytes. Using a
radioimmunoassay which measures CSb-9 in serum, we found that there was no generation of SC5b-9 in serum
which had been incubated with trypanosomes. We concluded that, although trypanosomes activate the
alternative pathway of complement, they are not lysed, because the cascade does not continue beyond the
establishment of C3 convertase.
African trypanosomiasis (sleeping sickness) in humans is
characterized in part by decreased levels of C4 and C3 and
elevated levels of immunoglobulin M (IgM) in serum (12). In
humans, as well as in animal models, hypocomplementemia
has generally been attributed to activation of complement by
immune complexes containing parasite antigens (19). Studies
of patients with Trypanosoma brucei subsp. gambiense
infection (12) demonstrate low C4 levels in both early-
(before central nervous system involvement) and late-stage
disease. This C4 depletion is attributed to activation of the
classical pathway by immune complexes. There is also a
marked decrease in C3 levels in the early stages of Gambian
trypanosomiasis accompanied by a decrease in factor B
levels (12). Using a rhesus monkey model, Nagle et al. (23)
demonstrated the deposition of properdin in glomerular
capillary walls of T. brucei subsp. rhodesiense-infected
animals. Thus, in trypanosomiasis, the alternative pathway
of complement may also be activated by circulating immune
complexes.
To date, it has not been established whether the observed
hypocomplementemia in humans with T. brucei subsp.
gambiense or T. brucei subsp. rhodesiense infections is due,
at least in part, to activation of complement by the parasites
themselves. However, there is evidence that other African
trypanosomes may directly activate complement. Variant
surface glycoprotein purified from T. brucei subsp. brucei
activates the classical pathway in an antibody-independent
fashion (22). T. congolense directly activates both the clas-
sical (24) and alternative pathways (32) in the serum of its
specific host, cattle. It is unclear whether this activation is
related to the decreased levels of early complement compo-
nents in serum seen in infected calves (25).
Complement is apparently unable to prevent the establish-
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ment of either T. brucei subsp. rhodesiense or T. brucei
subsp. gambiense in the bloodstream. The aim of this study
was to examine why the human complement system is
apparently ineffective in mediating killing of T. brucei subsp.
gambiense. We demonstrated for the first time that live T.
brucei subsp. gambiense are capable of activating the alter-
native pathway of complement in human serum. There is,
however, no lytic activity, because the cascade does not
continue beyond establishment of C3 convertase on the
trypanosome surface.
MATERIALS AND METHODS
Trypanosomes. T. brucei subsp. gambiense used in these
experiments were from the TxTat 1 line obtained from J. R.
Seed, University of North Carolina, Chapel Hill. BALB/cCr
or C3HeB/FeJ mice were inoculated with sufficient numbers
of trypanosomes from frozen stocks to produce fulminating
parasitemia 30 to 60 h postinoculation. Blood was drawn by
cardiac puncture with 3.2% sodium citrate (9 parts blood to
1 part sodium citrate) as an anticoagulant.
Trypanosomes were separated from blood cells and
plasma proteins by DEAE-cellulose chromatography (18).
All experiments were run with freshly isolated trypanosomes
kept at 4°C in Lanham's phosphate-buffered saline (60 mM
NaPO4, 44 mM NaCl [pH 8.0] containing 1.5% glucose)
(LPBSG). In all cases, the concentration of cells was deter-
mined by automated cell counting with a Coulter counter
(70-,um aperture). One-in-five hundred dilutions were
counted five times, and the mean of the corrected counts was
used as the cell count.
Complement sources. Normal human serum (NHS) was
collected by venipuncture from volunteer donors and stored
at -70°C for no longer than 60 days before use. For some
experiments, NHS was made 20 mM with respect to either
EDTA or ethylene glycol-bis(P-aminoethyl ether)-
223
224 DEVINE ET AL.
N,N,N',N'-tetraacetic acid (EGTA) by incubating serum for
5 min at 37°C with 0.1 volume of a 0.2 M neutralized (pH 7.2)
stock of the appropriate chelator. Such sera are referred to
as E-NHS or EG-NHS, respectively. E-NHS that had been
made 25 mM MgCl2 by addition of 0.1 volume of 0.25 M
MgCl2 is referred to as E-NHS-Mg2+. C3 (33) and factor B
(27) were purified from NHS. Functionally pure human
factor D was made by the method of Lambris et al. (17).
Factor B was radiolabeled with 125I (Amersham Corp.) with
lodogen (Pierce Chemical Co.) and the manufacturer-
recommended methodology. 125I-labeled factor B was used
within 24 h of labeling.
Antisera. Mouse monoclonal anti-human C3c was the gift
of Gordon D. Ross, University of North Carolina, Chapel
Hill. This antibody reacts with cell-bound C3b or iC3b.
Mouse monoclonal anti-human polymerized C9 (poly-C9)
(clone MBM-5) recognizes a neoantigen expressed by
MC5b-9 and poly-C9 but not monomeric C9 (7). Anti-C3c
and anti-poly-C9 were purified from ascitic fluid by ammo-
nium sulfate precipitation and DEAE-cellulose chromatog-
raphy. Mouse monoclonal anti-human IgG (Fc) (clone GG-5)
was purchased as ascitic fluid (Miles Scientific) and purified
by caprylic acid-ammonium sulfate precipitation (29). For
some experiments, these monoclonal antibodies were la-
beled with 125I as described above.
A 251I-labeled F(ab')2 fragment of sheep anti-mouse immu-
noglobulin was purchased from Amersham. Polyclonal goat
anti-human factor B (immunoglobulin fraction) was pur-
chased from Miles Scientific. Goat anti-human C5 was
prepared with purified C5 (33). Fluorescein isothiocyanate
(FITC)-conjugated probes included FITC-F(ab')2 rabbit anti-
goat IgG (Miles-Yeda), FITC-F(ab')2 rabbit anti-goat IgG
(Jackson Immunoresearch Laboratories), and FITC-goat
anti-mouse IgG (Cappel Laboratories).
Alternative pathway activation. We studied the activation
of the alternative pathway by T. brucei subsp. gambiense in
whole serum by incubating equal volumes of trypanosomes
at 2 x 107/ml and NHS, E-NHS, or EG-NHS for 30 min at
37°C, washing them three times by centrifugation at 4°C with
ice-cold LPBSG, and then assaying them for the presence of
bound complement components as described below. Depo-
sition of C3 onto trypanosomes was also studied in a purified
component system by incubating 250 ,lI of trypanosomes at
2 x 107/ml for 30 min at 37°C with 250 ,ul of LPBSG
containing either: (i) 3 mg of C3, 500 ,ug of factor B, 50 jig of
crude factor D, and 20 mM Mg2+ or (ii) 3 mg of C3 alone.
Cells were then washed and assayed for cell-bound C3 as
described below.
The ability of human serum to lyse trypanosomes by
complement activation was assayed by incubating
trypanosomes with NHS in microtiter plates for 30 min at
37°C as previously described (9). Wells were examined for
possible lysed cells with a Zeiss inverted-phase microscope.
Killed cells were defined as those which were nonmotile or
of abnormal shape.
Assay of complement binding with 1251-labeled antibodies.
One hundred microliters of trypanosome suspension treated
as described above was incubated with 100 ,ul of 251I-labeled
monoclonal antibody. Anti-C3c and anti-human IgG were
used at a concentration of 10 ,ug/ml, and anti-poly-C9 was
used at 15 ,ug/ml. After incubation for 20 min at room
temperature, three 50-pA samples were removed and spun
through a mixture of phthalate esters (1.5 parts n-butyl
phthalate [Fisher Scientific Co.] to 1.0 part bis(2-ethylhexyl)
phthalate [Eastman Kodak Co.]) in 400-,u Microfuge (Beck-
man Instruments, Inc.) tubes to separate cell-bound anti-
body from unbound antibody. The tube tips containing the
pelleted trypanosomes were cut off and counted in a gamma
counter.
The number of monoclonal antibody molecules bound per
cell was calculated from cell counts and the specific activity
of the antibody used. Specific antibody binding was defined
as molecules bound per cell in samples exposed to serum
minus molecules bound per cell in samples incubated in
buffer. Monoclonal anti-C3c shows a 1:1 binding stoichiom-
etry with erythrocyte-bound C3b (27). At the concentration
of anti-C3c used in these experiments, typical nonspecific
background binding is about 1,000 molecules per human
erythrocyte or about 2,000 molecules per human platelet.
Monoclonal anti-IgG shows a 1:1 binding stoichiometry with
erythrocytes (S. Atwater-Boyd and W. F. Rosse, manu-
script in preparation) and detects about 67% of platelet-
bound IgG (30). Nonspecific background binding is about
600 molecules per erythrocyte and 1,200 molecules per
platelet. The binding stoichiometry of anti-poly-C9 has not
yet been determined. The ability of the assay to specifically
measure poly-C9 or MCSb-9 was assessed by measuring
antibody binding to normal human erythrocytes exposed to
serum and different amounts of complement-fixing cold
agglutinin anti-I. Typical background binding at the concen-
tration of anti-poly-C9 used is about 600 molecules per
erythrocyte and about 1,350 molecules per platelet. Such
antibody binding was not inhibitable by a 50x molar excess
of unlabeled anti-poly-C9. Data from binding studies were
analyzed with the Wilcoxon paired t test (37).
Trypanosomes were assayed for the presence of mouse
immunoglobulin on their surfaces by the method described
above with 125I-labeled F(ab')2 sheep anti-mouse immuno-
globulin; however, the trypanosomes were not pretreated
with any human serum or complement components.
Assay of complement binding by cytofluorography. Cell-
associated fluorescence was measured with an Ortho Diag-
nostics, Inc., 50H cytofluorograph. Cells were illuminated
with the 488-nm line of an argon ion laser. Right-angle light
signals were focused onto appropriate fiber optics with a
Leitz 32x-0.40 NA objective mounted in a carrier of local
design. Fluorescence was measured behind a 515- to 530-nm
band-pass filter. Fluorescence signals were gated on the
basis of a right-angle versus forward light scatter cytogram
to restrict analysis to signals from single cells. Amplifiers
were set in the linear area mode. Data were analyzed with
the software in an Ortho 2140 data handling system. For
statistical analysis of histograms, two regions were defined.
Region 1 encompassed channels 1 to 999 to exclude material
in the last channel; this effectively eliminated unweighted
off-scale data from statistical analysis. Fewer than 2% of
total gated counts were in channel 1000. Region 2 was
arbitrarily set with the lower channel at the base of the right
shoulder of the histogram of the negative cell population.
Cells incubated with nonimmune serum and then FITC-
conjugated second antibody were used to define negative
populations.
Cells treated with NHS, E-NHS, or E-NHS-Mg2+ were
washed as described above and then incubated with unla-
beled goat anti-human factor B or nonimmune goat serum for
30 min at 4°C. After three washings with cold LPBSG, the
samples were incubated with FITC-labeled rabbit anti-goat
IgG antibody for 30 min at 4°C. Following two washings in
cold LPBSG, the trypanosomes were suspended at 106/ml,
and the suspension was made 1% formaldehyde to fix the
cells.
A similar assay was used to examine MC5b-9 and poly-C9
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TABLE 1. Binding of 125I-labeled monoclonal antibodies to T. brucei subsp. gambiense-data are reported as molecules of
antibody per cell
Monoclonal Molecules of antibody/cell on trypanosomes incubated with:
antibody against NHS E-NHS E-NHS-Mg2+ EG-NHS LPBSG
Human IgG (Fc)
No. 1 4,321 5,532 5,388 4,028
No. 2 1,679 3,147 3,817 6,096
Human C3C
No. 1 9,547 2,486a 13,524 2,709
SBb 6,838 0 10,815
No. 2 17,867 11,372a 39,742 9,908
SB 7,959 1,464 29,834
No. 3 12,848 10,250 4,160
SB 8,688 6,090
No. 4 15,804 2,971a 88,928 2,595
SB 13,209 376 86,333
Human poly-C9
No. 1 2,768 2,679 1,296 1,389
No. 2 1,470 1,180 1,753 1,301
a The difference between the value and that of the LPBSG control was not statistically significant.
b SB, Molecules of antibody specifically bound.
binding and C5 binding. In these experiments, the first
antibody was either monoclonal anti-poly-C9 (10 ,ug/ml) or
polyclonal goat anti-C5 (diluted 1:200) described above,
followed by FITC-conjugated goat anti-mouse IgG or FITC-
F(ab')2 rabbit anti-goat IgG, respectively. Incubations and
washings were as described above.
Positive control cells for detection ofC5 and poly-C9 were
made by depositing complement on the surface of normal
human erythrocytes. This was done by incubating equal
volumes of NHS, a dilution of cold agglutinin anti-I, and
normal human erythrocytes at a cell concentration of 5 x
107/ml for 20 min at 0°C and 60 min at 37°C. Washed
erythrocytes were then incubated with first and second
antibodies as described before. Human erythrocytes were
chosen as the control for antibody binding studies because
they have a surface area of 145 ,um2 (36), which is compa-
rable to the 113-p.m2 estimated surface area of trypanosomes
(2).
Binding of 125I-labeled factor B. To measure activation of
the alternative pathway by a direct method, we incubated
200 p.l of T. brucei subsp. gambiense (2 x 107/ml in LPBSG)
for 30 min at 37°C with 200 p.l of NHS, E-NHS, E-NHS-
Mg2+, or LPBSG, each containing 10 ,ug of purified 125I1
factor B. Three 120-,ul samples were removed from each
incubation mixture and spun through phthalate esters as
described above. The molecules of factor B bound per cell
were calculated from the specific activity of the reagent.
Measurement of C5b-9 in serum. Sera which had been
incubated with T. brucei subsp. gambiense were assayed for
the presence of soluble SC5b-9 complexes by radioimmuno-
assay. Trypanosomes at 2 x 107/ml in LPBSG were incu-
bated with an equal volume ofNHS or E-NHS. Samples (200
p.l) were removed at 0, 1, 2, 5, 10, 15, and 30 min after
incubation at 37°C. Cells were removed by centrifugation,
and supernatant fluids were frozen at -70°C until assayed.
Details of this solid-phase competitive inhibition radioim-
munoassay have been described elsewhere (6). Briefly, 50-,ul
immunobeads (Bio-Rad Laboratories) bearing rabbit anti-
mouse immunoglobulin were incubated with monoclonal
anti-poly-C9 for 1 h at room temperature in gelatin-coated
polypropylene tubes. The beads were then washed three
times with phosphate-buffered saline containing 0.05%
Tween (Sigma Chemical Co.). Sixty microliters of sample
serum and 90 RI of phosphate-buffered saline containing 1%
sodium desoxycholate (Fisher) were added to each assay
tube. After incubation for 1 h at room temperature, 1 ng of
125I-labeled poly-C9 was added, and the incubation was
continued for-90 min. The beads were then counted, washed,
and recounted, and the ratio of counts bound to counts
added was determined. A standard curve was constructed
with NHS containing increasing amounts of unlabeled puri-
fied poly-C9. The positive control for the NHS used was to
incubate 1 ml of serum with 300 ,ug of endotoxin for 30 min
at 37°C to generate SC5b-9. All samples were run in dupli-
cate. SCSb-9 values are expressed in units equivalent to
units of poly-C9, where one unit of poly-C9 is approximately
50 ng.
RESULTS
Trypanosomes incubated in NHS or NHS treated with
EDTA, EGTA, or magnesium were not lysed. All cells seen
in the lytic assay were motile and of normal shape. Never-
theless, C3 deposited on the surfaces of these trypanosomes
when the parasites were incubated with NHS or EG-NHS
but not when they were incubated with E-NHS. The addition
of 25 mM Mg2+ to E-NHS restored the ability of C3 to bind
to trypanosomes; C3 binding in E-NHS-Mg2+ was always at
least as great as the level of NHS and often significantly
greater than binding in NHS. The amount of C3 deposited
was the same after 20 or 30 min of incubation in serum. All
results reported here are from 30-min incubations. Because
the amount of complement components detected on the
surface of a trypanosome varied from one experiment to
another and one donor serum to another, representative
experiments are shown in Table 1. The amount of anti-C3c
bound to NHS- or E-NHS-Mg2+-treated trypanosomes was
significantly greater than the amount bound to either E-
NHS-treated cells or LPBSG buffer controls (T' = 0, P <
0.005).
In two experiments, trypanosomes incubated in purified
C3 were able to deposit 8,000 or 9,500 molecules of C3 on
their surfaces as measured by I251-labeled monoclonal anti-
C3c binding. The addition of factor B, factor D, and magne-
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TABLE 2. Binding of 125I-labeled factor B to T. brucei
subsp. gambiensea
Molecules/cell ± SD on trypanosomes incubated with
1251I-labeled factor B plus:
Expt. 1 mg of C3
no. + 20 mM
NHS E-NHS E-NHS-Mg2+ Mg2+ + 20 LPBSG
p.g of
factor D
1 212 ± 29 137 ± 23 254 ± 24 562 ± 43 17 ± 12
2 278 ± 27 101 ± 17 273 ± 34 664 ± 38 28 ± 8
a Two representative experiments are shown; data are reported as mole-
cules per cell ± one standard deviation.
sium ions increased deposition to 30,000 or 27,000 molecules
per cell, respectively.
Radiolabeled factor B binding experiments demonstrated
that incubation in NHS, E-NHS-Mg2 , or the C3-factor
D-Mg2+ mixture containing 1251-factor B resulted in an
increased amount of factor B bound to the surface compared
with those cells incubated in E-NHS (Table 2). A nearly
sixfold increase in factor B binding was seen in purified
component experiments in which there was no unlabeled
factor B to compete with the labeled factor B for binding
sites.
Deposition of factor B on the surface of trypanosomes
which had been exposed to NHS or E-NHS made 25 mM
Mg2+ (E-NHS-Mg2+) was detected by flow cytometric anal-
ysis. No binding of anti-factor B antibody was detected on
trypanosomes incubated in E-NHS (Fig. 1) or LPBSG (data
not shown).
Binding studies with 125I-labeled monoclonal anti-poly-C9
demonstrated that C9, in its activated form as either MC5b-9
or the polymer form, was not found on the trypanosome
surface under any conditions (Table 1). Antibody binding
could not be inhibited by a 50x molar excess of unlabeled
antibody; therefore, the bound antibody represented non-
specific binding. At the same concentration used in these
experiments, human erythrocytes exposed to cold agglutinin
anti-I antibody and NHS bound as many as 9,500 anti-poly-
C9 molecules. On erythrocytes containing amounts of C3
similar to that on the trypanosomes, 4,000 to 5,000 molecules
of anti-poly-C9 were bound. Greater than 70% of this binding
was inhibited by addition of a 5Ox molar excess of unlabeled
anti-poly-C9 (data not shown). In addition, poly-C9 was not
detected on serum-treated trypanosomes by flow cytometry
with unlabeled monoclonal anti-poly-C9 and FITC-con-
jugated anti-mouse IgG. The mean channel number (± the
standard deviation) of region 1 of the nonimmune ascites
control was 231.9 (± 100.2), while the region 1 mean of the
anti-poly-C9-treated sample was 236.8 (± 104.7). Anti-poly-
C9 binding to complement-containing erythrocytes could be
detected by flow cytometry (Fig. 2).
By flow cytometry, C5 was not detected on trypanosomes
exposed to NHS, E-NHS, or E-NHS-Mg2+. For NHS-
treated cells, the region 1 mean channel number was 27.1 for
nonimmune goat serum incubation and 56.5 for goat anti-C5
incubation. The control mean for E-NHS-treated cells was
25.0, and the anti-C5 mean was 23.9. E-NHS-Mg2+-treated
cells incubated with nonimmune goat serum had a mean
fluorescence of 24.5, while anti-C5-treated cells had a region
1 mean of 36.9. With the identical first and second antibody
regimen, C5 could readily be detected on erythrocytes
treated with various dilutions of anti-I and NHS as described
above (Fig. 2). The amount of C3 bound to these erythro-
cytes as measured by 125I-anti-C3c binding was similar to the
amount on the surfaces of trypanosomes (6,000 to 50,000
molecules per cell).
The radioimmunoassay for serum C5b-9 failed to detect
the generation of SCSb-9 in either NHS or E-NHS incubated
with T. brucei subsp. gambiense which had been incubated
for up to 30 min. This experiment was repeated on three
different occasions with identical negative results. Sample
duplicates were within 10% of their mean, and the standard
curves run with each experiment gave r values of greater
than 0.95 with virtually identical slopes. In control experi-
ments designed to demonstrate that the complement path-
ways in these sera were active and that we could detect
SCSb-9 complexes if they were formed, two of the same
three serum samples not exposed to trypanosomes were
treated with bacterial endotoxin as previously described (6)
and assayed for SCSb-9. Significant amounts of SCSb-9 were
detected (18 U).
Two types of experiment were done to evaluate the
possible contribution of immunoglobulin to activation of
complement by trypanosomes. First, we determined that the
freshly purified T. brucei subsp. gambiense used for these
experiments did not have detectable amounts of murine
immunoglobulin on their surfaces. The amount of 1251
labeled sheep anti-mouse immunoglobulin per cell was less
than that bound to erythrocytes or platelets incubated with
nonimmune mouse monoclonal IgG. Second, we could not
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FIG. 1. Histograms of anti-factor B binding detected by flow
cytometry. Shaded regions represent nonimmune serum controls.
The mean channel number of region 1 + the standard deviation and
the percentage of cells in region 2, respectively, were as follows:
NHS (top) control = 221.4 + 83.7 and 14.6%, anti-factor B = 306.2
+ 127.4 and 47.1%; E-NHS (middle) control = 194.5 + 71.6 and
6.9o; anti-factor B = 204.6 ± 83.1 and 9.5%; E-NHS-Mg2+ (bottom)
control = 241.2 - 83.0 and 22.3%; and anti-factor B = 325.7 - 130.3
and 52.4%.
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FIG. 2. Detection of polyclonal anti-C5 and monoclonal anti-poly-C9 binding to sensitized erythrocytes by flow cytometry and anti-C3c
binding by radioimmunoassay. Anti-I concentration of 0 represents cells incubated in buffer and NHS under the same conditions as cells
exposed to anti-I and human serum. Antibody incubations were performed as described in Materials and Methods. The mean channel number
is the mean of region 1 (channels 1 to 999). Symbols: *, anti-C5; *, anti-poly-C9; 0, anti-C3c.
detect any human IgG bound to trypanosomes that had been
incubated in NHS for 30 min at 37°C.
DISCUSSION
We have demonstrated that intact living African try-
panosomes of the T. brucei subgroup can activate comple-
ment when incubated in NHS. Deposition of C3 onto the
surfaces of these cells was inhibited by the addition of 20
mM EDTA and could be restored by 25 mM magnesium ion.
However, C3 deposition was not inhibited by addition of 20
mM EGTA. Furthermore, C3 deposition in a purified com-
ponent system was enhanced by addition of factors B and D.
These observations suggest that the activation of comple-
ment is via the alternative pathway (11). This conclusion is
further supported by the observation that factor B was also
found on the surfaces of serum-treated trypanosomes. The
number of molecules of factor B detected per cell in the
direct binding assay was probably lower than the number
actually present, as there was approximately four times as
much unlabeled factor B (200 F±g/ml) as labeled factor B in
the serum used in the experiments (21). Trypanosomes
incubated in E-NHS-Mg2+ showed a marked increase in C3
binding. The reason for this increase is unclear.
No murine or human immunoglobulin was detected on the
trypanosomes; therefore, complement activation was not
due to classical pathway activation. It is possible that some
amount of murine C3 was covalently bound to the surfaces
of column-purified trypanosomes, but we did not investigate
this possibility. If some of this C3 was in the C3b form, it
could possibly serve as a nidus for the formation of an
alternative-pathway C3 convertase by human complement
components. However, the trypanosomes are not killed by
complement in vivo, and we showed in vitro that con-
vertases formed in human serum are quickly restricted.
These observations suggest that C3b bound to trypanosomes
in vivo is rapidly inactivated.
Complement was not lytic for even a subpopulation of
trypanosomes exposed to human serum. This is consistent
with the observation that bloodstream forms of African
trypanosomes with an intact surface coat are not lysed by
complement (10). Complement was not lytic, because there
was no formation of the membrane attack complex, CSb-9.
The assays used in these studies could readily detect C5 and
MC5b-9 on the surface of a cell with a surface area similar to
that of a trypanosome. However, we were unable to detect
either C5 or MC5b-9 on the surfaces of T. brucei subsp.
gambiense exposed to human serum. Arguably, the binding
stoichiometry of monoclonal anti-poly-C9 on the parasite
surface may be very different from that on erythrocytes;
however, it is quite unlikely that polyclonal anti-C5 would
fail to detect C5 bound to trypanosomes. Indeed, our control
experiments demonstrated that our assays could readily
detect C5 on erythrocytes bearing similar amounts of C3.
Thus, the alternative-pathway C3 convertase apparently is
not able to form C5 convertase with neighboring C3b mole-
cules on the trypanosome surface; hence, no CSb is gener-
ated. This is unlike some bacterial systems in which the
membrane attack complex is formed but is not able to
penetrate the bacterial cell wall to insert into the cell
membrane and lyse the cell (14, 15). Sialic acid on the
surface of certain bacteria (5), as well as on mammalian cells
(8, 16, 26), plays a role in destabilizing C3 convertase by
promoting the binding of factor H. Although sialic acid has
not been described to be among the surface carbohydrates of
T. brucei subgroup trypanosomes (13), it has been reported
to account for the charge heterogeneity of the variable
surface glycoprotein of T. congolense (28). Trypanosome
surface components may destabilize alternative-pathway C3
convertase directly or by potentiating factor H binding. In a
preliminary report, Joiner et al. (K. A. Joiner, A. Sher,
L. V. Kirchhoff, T. Gaither, and C. H. Hammer, Fed. Proc.
44:1173, 1985) have recently stated that factor H binding is
promoted on the surface of metacyclic trypomastigote forms
of T. cruzi. Whether classical pathway activation by
trypanosomes (24), trypanosome fractions (22), or specific
antibody can be regulated by similar mechanisms is un-
known.
Our studies suggest a new interpretation of the interaction
between complement and the trypanosome surface. It has
been previously demonstrated that an intact complement
system is required for killing of T. rhodesiense in immune rat
serum (4, 19). Trypanosomes are known to be able to cap
parasite-specific antibody (31) or otherwise inactivate sur-
face immune complexes (1) when incubated at 37°C. Binding
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of antibody may cause the trypanosome to shed or reorga-
nize enough of its surface coat to be lysed by complement.
The procyclic forms of T. brucei, which lack a surface coat,
are susceptible to complement-mediated cytolysis (34, 20).
Ferrante and Allison (10) described a coatless form of T.
congolense which is lysed by human serum, whereas the
coated parent strain is not. These observations have led to
the conclusion (35) that the surface coat protects the blood-
stream (trypomastigote) forms from cytolysis by covering
underlying molecules which activate the alternative path-
way. The data reported here demonstrate that viable blood-
stream forms with an intact surface coat still display activa-
tor surfaces for the alternative pathway of complement.
Rather than masking underlying molecules, the variant sur-
face glycoprotein or other surface molecules may protect
against cytolysis by regulating complement activation on the
trypanosome surface. This possibility is particularly signifi-
cant in light of data from animal models suggesting that
terminal complement components play little role in control-
ling T. rhodesiense infections (3).
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